FOXO4-DRI

FOXO4-DRI is a synthetic D-retro-inverso (DRI) peptide derived from the FOXO4 transcription factor, designed to disrupt FOXO4-p53 protein-protein interactions and selectively induce apoptosis in senescent cells. It is one of the first-generation senolytic peptides — compounds designed to clear senescent (zombie) cells that accumulate with aging and drive age-related dysfunction. FOXO4-DRI is not approved for any medical indication and is sold strictly as a research-use-only compound by third-party laboratories.

What is FOXO4-DRI and how does the senolytic mechanism work?

FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 protein-protein interaction, releasing p53 to induce apoptosis selectively in senescent cells. The D-retro-inverso modification (reversed sequence with D-amino acids) provides protease resistance and improved bioavailability while preserving the FOXO4-binding interface. The compound was developed by Peter de Keizer's group at Erasmus MC and is among the most direct senolytic mechanism approaches in development.

Evidence level: preclinical (rodent aging models, cell culture senescence assays); no human clinical trials

What does the research show for FOXO4-DRI?

In preclinical rodent studies, FOXO4-DRI has shown selective elimination of senescent cells with restoration of fitness markers, fur density, and renal function in aged mice. The original Cell publication (Baar et al., 2017) demonstrated improved healthspan markers in aged mice receiving FOXO4-DRI. No published human clinical trials exist as of August 2026. The senolytic mechanism remains hypothesis-driven at the human level despite the compelling preclinical case.

Source: Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging, Baar M.P., Brandt R.M.C., … Demaria M., … de Keizer P.L.J., Cell, 2017 · Evidence level: preclinical (rodent and cell culture); no human clinical trials

How does FOXO4-DRI compare to other longevity-targeted compounds?

FOXO4-DRI is mechanistically distinct from other longevity-targeted compounds — it targets senescent cell clearance specifically, not telomerase activation, mitochondrial function, or NAD+ pathways.

What are the documented side effects of FOXO4-DRI?

Human safety data for FOXO4-DRI is essentially absent — no published Phase 1 or later trials. Preclinical rodent studies have not surfaced significant toxicity at researched doses, but the senolytic mechanism raises theoretical concerns about effects on non-senescent stem cell populations and immune function. Long-term safety in humans is completely unknown. FOXO4-DRI works by perturbing the FOXO4-p53 interaction to force senescent cells into apoptosis, and p53 is a central tumor-suppressor and cell-death regulator with roles far beyond senescence — so the systemic consequences of pharmacologically shifting p53 activity in a living human, including effects on healthy proliferating tissues, are entirely uncharacterized. No study has established a safe human dose, route, or exposure limit. Because there is zero human safety data and the mechanism acts on a master apoptosis switch, self-experimentation with FOXO4-DRI carries risks that cannot currently be quantified; this page is educational and is not a protocol.

Evidence level: preclinical safety only; no human safety data

What is the regulatory status of FOXO4-DRI?

FOXO4-DRI is not approved for any medical indication anywhere in the world as of August 2026. No active human clinical trial program has been registered for FOXO4-DRI. The compound is sold strictly as a research-use-only material by third-party laboratories. Buyers should treat FOXO4-DRI as an extremely early-stage research compound with promising preclinical data but no human evidence. Regulatory context in are peptides legal regulatory status by country.

Why does FOXO4-DRI vendor verification matter for an early-stage compound?

Because FOXO4-DRI's structural complexity (D-retro-inverso modification, specific sequence binding the FOXO4-p53 interface) makes proper synthesis quality control critical — incorrectly synthesized material may not produce the intended senolytic effect or may have altered toxicity profile. Independent HPLC purity testing and mass spectrometry identity confirmation are essential. Guidance in how-to-test-peptides hub.

How does Peptigrity verify FOXO4-DRI vendors?

Peptigrity collects independent third-party Certificates of Analysis for FOXO4-DRI from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. Methodology in how we calculate trust scores.

Frequently asked questions

What does FOXO4-DRI do?

FOXO4-DRI is designed to selectively eliminate senescent (zombie) cells that accumulate with aging by disrupting the FOXO4-p53 protein interaction, releasing p53 to induce apoptosis in senescent cells. Preclinical rodent studies have shown improvements in aging markers, but human evidence is absent.

Is FOXO4-DRI effective in humans?

No human clinical trials of FOXO4-DRI have been published as of August 2026. The senolytic mechanism remains hypothesis-driven at the human level despite compelling preclinical results in rodent aging models.

Is FOXO4-DRI legal to purchase?

FOXO4-DRI is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.

Will FOXO4-DRI be FDA-approved?

No active FDA clinical development program for FOXO4-DRI exists as of August 2026. Senolytic compounds as a class are an active area of research, but FOXO4-DRI specifically has not advanced into formal clinical development.

How can I verify a FOXO4-DRI vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation appropriate to a D-retro-inverso peptide. Mass spec is essential because synthesis errors in the D-amino acid configuration could produce inactive material that appears similar on HPLC. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a FOXO4-DRI dose?

No. FOXO4-DRI is not approved for human consumption, has no published human clinical data, and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician, with particular awareness that translation from rodent dosing to human use is highly uncertain.

This section is for educational and informational purposes only and does not constitute medical advice. FOXO4-DRI is not approved by the FDA or any other regulator for human use and has no published human clinical trial data. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.